SG11201508071VA - C. novyi for the treatment of solid tumors in humans - Google Patents
C. novyi for the treatment of solid tumors in humansInfo
- Publication number
- SG11201508071VA SG11201508071VA SG11201508071VA SG11201508071VA SG11201508071VA SG 11201508071V A SG11201508071V A SG 11201508071VA SG 11201508071V A SG11201508071V A SG 11201508071VA SG 11201508071V A SG11201508071V A SG 11201508071VA SG 11201508071V A SG11201508071V A SG 11201508071VA
- Authority
- SG
- Singapore
- Prior art keywords
- novyi
- humans
- treatment
- solid tumors
- tumors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361806497P | 2013-03-29 | 2013-03-29 | |
| PCT/US2014/032196 WO2014160950A1 (en) | 2013-03-29 | 2014-03-28 | C. novyi for the treatment of solid tumors in humans |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201508071VA true SG11201508071VA (en) | 2015-10-29 |
Family
ID=51625539
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201508071VA SG11201508071VA (en) | 2013-03-29 | 2014-03-28 | C. novyi for the treatment of solid tumors in humans |
| SG10201902765VA SG10201902765VA (en) | 2013-03-29 | 2014-03-28 | C. novyi for the treatment of solid tumors in humans |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201902765VA SG10201902765VA (en) | 2013-03-29 | 2014-03-28 | C. novyi for the treatment of solid tumors in humans |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10617723B2 (en) |
| EP (3) | EP2988760B1 (en) |
| JP (6) | JP6756609B2 (en) |
| KR (1) | KR20160021084A (en) |
| CN (2) | CN105451750B (en) |
| AU (2) | AU2014240872A1 (en) |
| BR (2) | BR122020006408B1 (en) |
| CA (2) | CA3206655A1 (en) |
| DK (1) | DK2988760T3 (en) |
| ES (2) | ES2922378T3 (en) |
| HK (1) | HK1222134A1 (en) |
| IL (1) | IL241823B (en) |
| MX (1) | MX2015013784A (en) |
| NZ (1) | NZ712691A (en) |
| PH (1) | PH12015502260A1 (en) |
| RU (1) | RU2718670C2 (en) |
| SG (2) | SG11201508071VA (en) |
| UA (1) | UA120036C2 (en) |
| WO (1) | WO2014160950A1 (en) |
| ZA (2) | ZA201507412B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2944456C (en) * | 2014-03-31 | 2023-10-31 | The Johns Hopkins University | Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies |
| CN105912930B (en) * | 2016-04-11 | 2019-02-01 | 北京奇虎科技有限公司 | Mobile terminal and its system resource method of controlling security |
| US10815534B2 (en) | 2016-08-23 | 2020-10-27 | Mayo Foundation For Medical Education And Research | Methods and materials for treating estrogen receptor positive breast cancer |
| AU2018269982A1 (en) * | 2017-05-16 | 2020-01-02 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating cancer with atypical BRAF mutations |
| CN109985039A (en) * | 2017-12-29 | 2019-07-09 | 深圳微芯生物科技股份有限公司 | For treating the combination medicine of leukaemia and its preparing the purposes in the drug for treating acute myeloid leukaemia |
| WO2021231611A1 (en) * | 2020-05-12 | 2021-11-18 | Splash Pharmaceuticals, Inc. | Methods for treating cancer using spl-108 polypeptide based on tp53 mutational status |
| US11717787B2 (en) * | 2021-01-04 | 2023-08-08 | Saudi Arabian Oil Company | High free volume membrane for gas separation |
| CN113855710B (en) * | 2021-10-09 | 2024-02-20 | 施慧达药业集团(吉林)有限公司 | Application of clostridium gossypii combined tumor angiogenesis inhibitor |
| CN115350145A (en) * | 2022-09-06 | 2022-11-18 | 华中科技大学同济医学院附属协和医院 | Application of bacteria-mediated metformin-loaded polypeptide hydrogel in tumor immunotherapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599331A (en) | 1984-12-24 | 1986-07-08 | Syntex (U.S.A.) Inc. | Etianic acids as antiangiogenics |
| EP0221705A1 (en) | 1985-10-23 | 1987-05-13 | The Upjohn Company | Tetrahydro angiostatic steroids |
| US4771042A (en) | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| EP0477195A1 (en) | 1989-06-16 | 1992-04-01 | The Upjohn Company | Suramin type compounds and angiostatic steroids to inhibit angiogenesis |
| CA2425841C (en) | 1991-11-22 | 2006-01-10 | Alcon Laboratories, Inc. | Angiostatic steroids |
| WO2002067796A1 (en) | 2001-02-28 | 2002-09-06 | Rex Medical, L.P. | Apparatus for delivering ablation fluid to treat neoplasms |
| EP1446012B1 (en) * | 2001-11-21 | 2013-07-17 | The Johns Hopkins University | Combination bacteriolytic therapy for the treatment of tumors |
| WO2005018332A1 (en) * | 2003-08-13 | 2005-03-03 | The General Hospital Corporation | Modified microorganisms for anti-cancer therapy |
| EP1675465B1 (en) | 2003-10-22 | 2010-03-03 | The Johns Hopkins University | Improved combination bacteriolytic therapy for the treatment of tumors |
| US20070015738A1 (en) * | 2005-07-15 | 2007-01-18 | Walker Stephen G | Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells |
| TW200819540A (en) * | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
| US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
-
2014
- 2014-03-28 CA CA3206655A patent/CA3206655A1/en active Pending
- 2014-03-28 EP EP14774988.1A patent/EP2988760B1/en active Active
- 2014-03-28 JP JP2016505594A patent/JP6756609B2/en active Active
- 2014-03-28 AU AU2014240872A patent/AU2014240872A1/en not_active Abandoned
- 2014-03-28 NZ NZ712691A patent/NZ712691A/en unknown
- 2014-03-28 BR BR122020006408-0A patent/BR122020006408B1/en active IP Right Grant
- 2014-03-28 DK DK14774988.1T patent/DK2988760T3/en active
- 2014-03-28 US US14/781,273 patent/US10617723B2/en active Active
- 2014-03-28 MX MX2015013784A patent/MX2015013784A/en active IP Right Grant
- 2014-03-28 EP EP22171112.0A patent/EP4108248A1/en active Pending
- 2014-03-28 CA CA2908508A patent/CA2908508C/en active Active
- 2014-03-28 WO PCT/US2014/032196 patent/WO2014160950A1/en active Application Filing
- 2014-03-28 CN CN201480028119.8A patent/CN105451750B/en active Active
- 2014-03-28 SG SG11201508071VA patent/SG11201508071VA/en unknown
- 2014-03-28 ES ES20167187T patent/ES2922378T3/en active Active
- 2014-03-28 CN CN202310166182.9A patent/CN116570628A/en active Pending
- 2014-03-28 RU RU2015146199A patent/RU2718670C2/en active
- 2014-03-28 BR BR112015024621-4A patent/BR112015024621B1/en active IP Right Grant
- 2014-03-28 SG SG10201902765VA patent/SG10201902765VA/en unknown
- 2014-03-28 UA UAA201510523A patent/UA120036C2/en unknown
- 2014-03-28 EP EP20167187.2A patent/EP3730146B1/en active Active
- 2014-03-28 ES ES14774988T patent/ES2815564T3/en active Active
- 2014-03-28 KR KR1020157031284A patent/KR20160021084A/en not_active Application Discontinuation
-
2015
- 2015-09-24 IL IL241823A patent/IL241823B/en active IP Right Grant
- 2015-09-29 PH PH12015502260A patent/PH12015502260A1/en unknown
- 2015-10-06 ZA ZA2015/07412A patent/ZA201507412B/en unknown
-
2016
- 2016-09-01 HK HK16110438.1A patent/HK1222134A1/en unknown
-
2017
- 2017-02-14 JP JP2017025263A patent/JP2017088619A/en active Pending
- 2017-09-21 ZA ZA2017/06402A patent/ZA201706402B/en unknown
-
2018
- 2018-10-26 JP JP2018201792A patent/JP2019011376A/en active Pending
-
2019
- 2019-01-17 AU AU2019200276A patent/AU2019200276B2/en active Active
-
2020
- 2020-03-31 US US16/836,003 patent/US11439669B2/en active Active
- 2020-06-25 JP JP2020109387A patent/JP7445893B2/en active Active
-
2021
- 2021-12-09 JP JP2021199949A patent/JP2022022392A/en active Pending
-
2022
- 2022-08-02 US US17/816,924 patent/US20220378852A1/en active Pending
-
2024
- 2024-03-06 JP JP2024034039A patent/JP2024056012A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3027192A4 (en) | Methods for the treatment of solid tumors | |
| IL243976A0 (en) | Kdm1a inhibitors for the treatment of disease | |
| IL273090B (en) | Methods and compositions for the treatment of cancer | |
| ZA201706402B (en) | C.novyi for the treatment of solid tumors in humans | |
| HK1221408A1 (en) | Combination therapy for the treatment of glioblastoma | |
| HUE057061T2 (en) | Combination therapy for the treatment of cancer | |
| EP3033079A4 (en) | Methods for the treatment of her2 amplified cancer | |
| HK1220324A1 (en) | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | |
| IL248767B (en) | Trimethoxyphenyl-benzimidazole compound for use in the treatment of cancer | |
| EP3007756A4 (en) | Catheter-assisted tumor treatment | |
| PT3089749T (en) | Combined preparations for the treatment of cancer | |
| HK1222548A1 (en) | Pharmaceutical combinations for the treatment of cancer | |
| HK1223547A1 (en) | Methods for the treatment of cancer | |
| EP3089745A4 (en) | Compounds, compositions, and methods for the treatment of cancers | |
| LT2984108T (en) | Anti-s100a7 antibodies for the treatment and diagnosis of cancer | |
| EP3016948B8 (en) | 2-acylaminothiazoles for the treatment of cancer | |
| EP3013332A4 (en) | Cancer treatment | |
| GB201300546D0 (en) | Cancer Treatment |